Last reviewed · How we verify

NCT06668948

The Prognostic Role of Fibrinogen to Albumin Ratio in Acute Leukemia Patients

Not yet recruiting Last updated 1 November 2024
What this trial tests

trial in Patients with Acute Leukemia in 90 participants. Not yet recruiting.

Timeline
1 October 2025
Primary endpoint
1 November 2025
1 December 2025

Quick facts

Lead sponsorAssiut University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment90
Start date1 October 2025
Primary completion1 November 2025
Estimated completion1 December 2025

Conditions studied

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Patients with Acute Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aim to investigate whether levels of acute phase reactants at diagnosis and after 6 months of follow-up correlate with survival and response to treatment in newly diagnosed acute leukemia.Ultimately, we will evaluate the fibrinogen/albumin ratio, a simple score based on acute phase protein levels, whether it can provide relevant prognostic information in acute leukemia patients at diagnosis and after 6 months of follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06668948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing